Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of Clinical Oncology
Volume35
DOIs
Publication statusPublished - 20 May 2017

Cite this